Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/26258

Title: Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities
Authors: Harrison, Richard P.
Ruck, Steven
Medcalf, Nick
Rafiq, Qasim A.
Keywords: Cell- and tissue-based therapy
Organizational innovation
Issue Date: 2017
Publisher: © The Authors. Published by Elsevier Inc. on behalf of the International Society for Cellular Therapy
Citation: HARRISON, R. ...et al., 2017. Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities. Cytotherapy, 19 (10), pp. 1140-1151.
Abstract: Decentralized or “redistributed” manufacturing has the potential to revolutionize the manufacturing approach for cell and gene therapies (CGTs), moving away from the “Fordist” paradigm, delivering health care locally, customized to the end user and, by its very nature, overcoming many of the challenges associated with manufacturing and distribution of high volume goods. In departing from the traditional centralized model of manufacturing, decentralized manufacturing divides production across sites or geographic regions. This paradigm shift imposes significant structural and organisational changes on a business presenting both hidden challenges that must be addressed and opportunities to be embraced. By profoundly adapting business practices, significant advantages can be realized through a democratized value chain, creation of professional-level jobs without geographic restriction to the central hub and a flexibility in response to external pressures and demands. To realize these potential opportunities, however, advances in manufacturing technology and support systems are required, as well as significant changes in the way CGTs are regulated to facilitate multi-site manufacturing. Decentralized manufacturing is likely to be the manufacturing platform of choice for advanced health care therapies—in particular, those with a high degree of personalization. The future success of these promising products will be enhanced by adopting sound business strategies early in development. To realize the benefits that decentralized manufacturing of CGTs has to offer, it is important to examine both the risks and the substantial opportunities present. In this research, we examine both the challenges and the opportunities this shift in business strategy represents in an effort to maximize the success of adoption.
Description: This work is made available according to the conditions of the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/
Sponsor: This study was supported by an Engineering and Physical Sciences Research Council (EPSRC) Engineering, Tissue Engineering and Regenerative Medicine (ETERM) Landscape fellowship grant (Richard Harrison) reference EP/I017801/1 and an EPSRC Fellowships in Manufacturing grant (Nicholas Medcalf) Reference EP/K037099/1.
Version: Published
DOI: 10.1016/j.jcyt.2017.07.005
URI: https://dspace.lboro.ac.uk/2134/26258
Publisher Link: http://dx.doi.org/10.1016/j.jcyt.2017.07.005
ISSN: 1465-3249
Appears in Collections:Published Articles (Mechanical, Electrical and Manufacturing Engineering)

Files associated with this item:

File Description SizeFormat
1-s2.0-S1465324917306321-main.pdfPublished version1.22 MBAdobe PDFView/Open


SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.